• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Tertiary amines

Introduction to 4-[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]morpholine (CAS No. 1073372-03-8)

4-[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]morpholine (CAS No. 1073372-03-8) is a versatile organic compound that has gained significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is a morpholine derivative with a boronic acid ester functionality, which makes it particularly useful in various synthetic transformations and as a building block in drug discovery.

The chemical structure of 4-[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]morpholine consists of a morpholine ring attached to a substituted pyridine moiety via a carbon linker. The presence of the boronic acid ester group (Bpin) provides this compound with unique reactivity and stability properties. The Bpin group is commonly used in Suzuki-Miyaura coupling reactions, which are widely employed in the synthesis of biologically active molecules and pharmaceuticals.

In recent years, the use of boronic acid derivatives in medicinal chemistry has expanded significantly due to their ability to form stable intermediates and facilitate the synthesis of complex molecules. 4-[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]morpholine is no exception and has been utilized in the development of several drug candidates. For instance, it has been employed in the synthesis of novel inhibitors for various therapeutic targets, including kinases and proteases.

The morpholine ring in 4-[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]morpholine contributes to its solubility and bioavailability properties. Morpholines are known for their ability to enhance the aqueous solubility of lipophilic compounds, making them valuable in the design of drug molecules that require good absorption and distribution profiles. Additionally, the morpholine ring can improve the metabolic stability of drug candidates by reducing their susceptibility to enzymatic degradation.

The pyridine moiety in 4-[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]morpholine imparts important pharmacological properties. Pyridine derivatives are often found in drugs targeting the central nervous system (CNS) and have been shown to exhibit various biological activities such as anti-inflammatory and anticonvulsant effects. The presence of a methyl substituent on the pyridine ring can further modulate these activities by influencing the compound's binding affinity to specific receptors or enzymes.

In terms of synthetic applications, 4-[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]morpholine serves as an excellent starting material for Suzuki-Miyaura cross-coupling reactions. These reactions are highly efficient and can be used to introduce a wide range of functional groups onto the pyridine ring. For example, aryl halides can be coupled with this compound to form biaryl structures that are common scaffolds in many bioactive molecules.

The versatility of 4-[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]morpholine has also been demonstrated in its use as a ligand in metal-catalyzed reactions. The Bpin group can be selectively removed under mild conditions to generate a boronic acid intermediate. This intermediate can then participate in other types of cross-coupling reactions or be further functionalized through other chemical transformations.

In addition to its synthetic utility, 4-[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]morpholine has shown promise in preclinical studies for its potential therapeutic applications. Research has indicated that this compound and its derivatives exhibit potent activity against certain cancer cell lines and may have potential as anti-cancer agents. The exact mechanism of action is still under investigation but is believed to involve modulation of key signaling pathways involved in cell proliferation and survival.

The safety profile of 4-[3-methyl-5-(4,4，5，5-tetramethyl-1，3，2-dioxaborolan-2-y l)- 2-pyrid yl]morp hol ine is an important consideration for its potential use as a pharmaceutical agent. Preclinical toxicology studies have shown that this compound exhibits low toxicity at therapeutic concentrations. However, further investigations are needed to fully understand its safety profile and potential side effects.

In conclusion, 4-[ 3-me th yl - 5 -( 4 , 4 , 5 , 5 -tet ram eth yl - 1 , 3 , 2 -d io xab or o lan - 2 - yl ) - 2 -pyri d yl ]mor ph ol ine (CAS No. 1073372–03–8) is a highly valuable compound with diverse applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and reactivity make it an attractive building block for the synthesis of novel drug candidates with promising therapeutic potential. Ongoing research continues to explore new avenues for its use and further optimize its properties for clinical applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)